Migraine drug ajovy put to the test for better sleep
NCT ID NCT04693533
First seen Jan 24, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This study looked at whether fremanezumab (Ajovy), an FDA-approved migraine prevention drug, can also improve sleep quality in people with migraine. Twenty-two adults with frequent migraines (10-25 headache days per month) received monthly injections for three months. Researchers tracked migraine days and sleep quality using questionnaires before and during treatment. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLEEP DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BIDMC Headaceh Clinic
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fremanezumab (Ajovy), a monthly anti-CGRP injection
What this could lead to
If successful, this could show that fremanezumab not only reduces migraine days but also improves sleep quality in migraine patients.
What could go wrong
The study was terminated early and enrolled only 22 people, so results are limited. It is a small, single-group design without a placebo control, making it hard to draw firm conclusions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.